The report is available in English with a French summary - KCE
The report is available in English with a French summary - KCE
The report is available in English with a French summary - KCE
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
122 Plasma <strong>KCE</strong> Reports 120<br />
APPENDIX 4: IMMUNO-HAEMATOLOGICAL<br />
SURVEY<br />
Use of immunoglobul<strong>in</strong>s <strong>in</strong> the treatment of immune deficiencies<br />
and other d<strong>is</strong>eases<br />
Th<strong>is</strong> <strong>in</strong>formation <strong>is</strong> asked by the <strong>KCE</strong> to project the future needs <strong>in</strong> immunoglobul<strong>in</strong>s (IG)<br />
<strong>in</strong> Belgium. Th<strong>is</strong> work has been requested by INAMI/RIZIV to prevent future IG<br />
shortages.<br />
Your data will not be d<strong>is</strong>tributed to any other <strong>in</strong>stitution, and will not be used to assess<br />
appropriateness of IG use <strong>in</strong> Belgian centers.<br />
If you have any question about th<strong>is</strong> survey or the project, you can contact:<br />
Dr Germa<strong>in</strong>e Hanquet, <strong>KCE</strong>, 02/287.33.37, germa<strong>in</strong>e.hanquet@kce.fgov.be<br />
Or Dr Michel Huybrechts, <strong>KCE</strong>, 02/287.33.42, michel.huybrechts@kce.fgov.be<br />
Thank you for your ass<strong>is</strong>tance!<br />
Name of the physician:………………………………………………………………….<br />
Name of the Centre / Hospital:…………………………………………………………<br />
In the first column (total patients followed), please <strong>in</strong>clude all patients that were seen <strong>in</strong><br />
your centre <strong>in</strong> 2008, regardless of treatment.<br />
1. For Primary Immune Deficiencies (PID) treated <strong>in</strong> your centre <strong>in</strong> 2008<br />
If th<strong>is</strong> <strong>in</strong>formation <strong>is</strong> not <strong>available</strong> for 2008, please provide data from other periods and<br />
specify.<br />
Treatment <strong>with</strong> <strong>in</strong>travenous immunoglobul<strong>in</strong>s<br />
Indications Total number patients Number of IG<br />
Average dose per<br />
followed <strong>in</strong> your perfusions<br />
perfusion <strong>in</strong> g/kg<br />
centre<br />
adm<strong>in</strong><strong>is</strong>tered <strong>in</strong> 2008 (or usual dose)<br />
PID <strong>in</strong> adults<br />
PID <strong>in</strong> children<br />
Comments:……………………………………………………………………………….<br />
Treatment <strong>with</strong> subcutaneous immunoglobul<strong>in</strong>s<br />
Indications Total number patients Number of IG<br />
Average dose per<br />
followed <strong>in</strong> your perfusions prescribed perfusion <strong>in</strong> g/kg<br />
centre<br />
<strong>in</strong> 2008<br />
(or usual dose)<br />
PID <strong>in</strong> adults<br />
PID <strong>in</strong> children<br />
Comments:……………………………………………………………………………….